Terms: = Germ cell tumor AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
666 results:
1. Safety and biological outcomes following a phase 1 trial of GD2-specific car-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract] [Full Text] [Related]
2. A Roadmap of car-T-cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
[TBL] [Abstract] [Full Text] [Related]
3. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
4. Identification and characterisation of novel car-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract] [Full Text] [Related]
5. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T cells through the Re-Education of tumor-Associated Microglia and Macrophages.
Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
[TBL] [Abstract] [Full Text] [Related]
6. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract] [Full Text] [Related]
7. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma.
Sakunrangsit N; Khuisangeam N; Inthanachai T; Yodsurang V; Taechawattananant P; Suppipat K; Tawinwung S
Cancer Immunol Immunother; 2024 Apr; 73(6):98. PubMed ID: 38619641
[TBL] [Abstract] [Full Text] [Related]
8. Mesenchymal-Stem-cell-Based Therapy against Gliomas.
Santillán-Guaján SM; Shahi MH; Castresana JS
Cells; 2024 Apr; 13(7):. PubMed ID: 38607056
[TBL] [Abstract] [Full Text] [Related]
9. Single-cell sequencing reveals VEGFR as a potential target for car-T cell therapy in chordoma.
Wu H; Li X; Zhang B; Liu P; Qi M; Du Y; Zhang C; Duan W; Chen Z
Br J Cancer; 2024 Jun; 130(10):1609-1620. PubMed ID: 38605247
[TBL] [Abstract] [Full Text] [Related]
10. Choosing T-cell sources determines car-T cell activity in neuroblastoma.
García-García L; G Sánchez E; Ivanova M; Pastora K; Alcántara-Sánchez C; García-Martínez J; Martín-Antonio B; Ramírez M; González-Murillo Á
Front Immunol; 2024; 15():1375833. PubMed ID: 38601159
[TBL] [Abstract] [Full Text] [Related]
11. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
12. Identification of genetic modifiers enhancing B7-H3-targeting car T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract] [Full Text] [Related]
13. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
[TBL] [Abstract] [Full Text] [Related]
14. CD19 car-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
[TBL] [Abstract] [Full Text] [Related]
15. Intrathecal bivalent car T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.
Bagley SJ; Logun M; Fraietta JA; Wang X; Desai AS; Bagley LJ; Nabavizadeh A; Jarocha D; Martins R; Maloney E; Lledo L; Stein C; Marshall A; Leskowitz R; Jadlowsky JK; Christensen S; Oner BS; Plesa G; Brennan A; Gonzalez V; Chen F; Sun Y; Gladney W; Barrett D; Nasrallah MP; Hwang WT; Ming GL; Song H; Siegel DL; June CH; Hexner EO; Binder ZA; O'Rourke DM
Nat Med; 2024 May; 30(5):1320-1329. PubMed ID: 38480922
[TBL] [Abstract] [Full Text] [Related]
16. Intraventricular carv3-TEAM-E T cells in Recurrent Glioblastoma.
Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
[TBL] [Abstract] [Full Text] [Related]
17. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
18. Locoregional delivery of IL-13Rα2-targeting car-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Apr; 30(4):1001-1012. PubMed ID: 38454126
[TBL] [Abstract] [Full Text] [Related]
19. Targeting Wnt signaling for improved glioma immunotherapy.
Gutova M; Hibbard JC; Ma E; Natri HM; Adhikarla V; Chimge NO; Qiu R; Nguyen C; Melendez E; Aguilar B; Starr R; Yin H; Rockne RC; Ono M; Banovich NE; Yuan YC; Brown CE; Kahn M
Front Immunol; 2024; 15():1342625. PubMed ID: 38449858
[TBL] [Abstract] [Full Text] [Related]
20. Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche.
de Oliveira KG; Bång-Rudenstam A; Beyer S; Boukredine A; Talbot H; Governa V; Johansson MC; Månsson AS; Forsberg-Nilsson K; Bengzon J; Malmström J; Welinder C; Belting M
Acta Neuropathol Commun; 2024 Feb; 12(1):35. PubMed ID: 38414005
[TBL] [Abstract] [Full Text] [Related]
[Next]
